A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Inclusion Criteria: * 1\. Adults aged 19 years or older * 2\. Diagnosed with type 2 diabetes * 3\. HbA1c level 7.0% ≤ HbA1c ≤ 10.0% * 4\. Stable administration of metformin (≥1,000 mg/day) and dapagliflozin (10 mg/day) without any change in dosage or formulation for at least 8 weeks prior to Visit 1 * 5\. 20 kg/m2 ≤ BMI ≤ 45 kg/m2 * 6\. Agree to the recommended exercise and diet regimen during this clinical trial Exclusion Criteria: * 1\. Patients with a history of allergy or resistance to the investigational drug or background therapy * 2\. Patients diagnosed with a type of diabetes other than type 2 diabetes * 3\. Patients with uncontrolled severe diabetic complications * 4\. Patients with a history of acute or chronic metabolic acidosis, including lactic acidosis or diabetic ketoacidosis. * 5\. Patients with a history of diabetic coma or precoma * 6\. Those with a history of severe hypoglycemia * 7\. Those whose weight change \> 5 kg * 8\. History of gastrointestinal disease or surgery * 9\. History of bariatric surgery * 10\. History of gallbladder disease * 11\. History of a disease that could affect the interpretation of HbA1c * 12\. History of acute or chronic pancreatitis or pancreatectomy * 13\. History (including family history) of medullary thyroid cancer (MTC) or multiple endocrine neoplasia (MEN2). * 14\. Uncontrolled hypertension * 15\. Severe infections or severe trauma * 16\. Malnutrition, starvation, or debility, as determined by the investigator. * 17\. P…